'So good or bad news?
Well first it is a surprise as CEO Severin Schwan announced at the Q2
numbers in July that the company will stay clear of large acquisitions, in
contrast to what many large pharmaceuticals are doing. Following the strategy
of buying smaller companies, Roche recently acquired US-based cancer drug maker
Seragon Pharmaceuticals for $1.7 billion and California-based startup Genia
Technologies for $350 million.
Chugai though is clearly a well-known entity to Roche. My view on price would be that US$10bn for a
company that currently generates around 4% of Roche’s operating cash flow (and
let’s call it 5% equivalent post any obvious post-deal synergies) is equivalent
to 4% of the current market cap i.e. a very fair price'
Now it sounds as if the Chugai deal is not going to go through as the Japanese management want too high a price for their stake. If you had told me that would be the outcome last week I would have taken management at their Q2 results word and assumed no more deals would be forthcoming. That was before the InterMune headlines of the last 24 hours.
Now Roche has a US$250bn+ market cap...and, as shown below, a light debt level so funding a proposed US$8.3bn is no problem. Is it a good deal however?
A couple of observations. First, whilst Roche guide that the transaction will be earnings neutral in 2015 and accretive from 2016 this reflects the "weird-ism" of a low interest rate time. Given InterMune was last annualising out at not much more than US$100m of revenues and was losing US$200m+ at the ebitda level indicates that the value is in potential.
The potential does sound good. IPF is a terrible disease and I note the combination of no competitors and a 'high unmet need' does offer huge scope to revenue and earnings accrual over time. Now the no competitors angle is not fully true as Boehringer (as detailed here) are also developing a treatment but important InterMune appear to be ahead - especially in North America where they are generating around US$40k per patient currently.
Additionally the two companies do know each other having collaborated a few years ago, have reasonably proximate office locations and the product portfolio is a reasonable fit:
As always the market is the ultimate arbiter...and Roche shares trading mildly up on the day says it all. In the wider scheme of things Roche has spent just over 3% of its market cap on an area where a hopeful market will see potential. Certainly the shift of the InterMune share price from below US$20 at the start of the year to over US$70 now shows how the perceived potential has changed.
Overall this deal does not really move the needle at Roche
BUT they certainly could have done worse things with their capital especially by spending more of it. My conclusion then is that the range
previously discussed (buy more at c. CHF250, top-slice at c. CHF275) remains
about right. The share also pays a just over 3% yield too.




No comments:
Post a Comment